Welcome to our dedicated page for Pulse Biosciences SEC filings (Ticker: PLSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulse Biosciences, Inc. (Nasdaq: PLSE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. As a medical device developer focused on bioelectric medicine and nanosecond pulsed field ablation (nsPFA) technology, Pulse Biosciences uses its SEC filings to describe clinical programs, financial performance, governance matters and key milestones for its nPulse platforms.
Investors can review Form 10-K and 10-Q filings for detailed discussions of the company’s business, risk factors, research and development spending and revenue from nPulse capital equipment and Vybrance disposables. Form 8-K current reports highlight material events such as FDA Investigational Device Exemption (IDE) approvals for the NANOCLAMP AF and NANOPULSE-AF atrial fibrillation studies, publication of first-in-human thyroid data, initiation of clinical trials, and quarterly business updates and financial results.
The company’s DEF 14A definitive proxy statement outlines corporate governance, board structure, equity incentive plans and executive compensation policies, providing insight into how management and directors are incentivized as Pulse Biosciences advances its nsPFA technology. Other exhibits and schedules within these filings can include information on stockholder votes, amendments to equity plans and non-GAAP financial measures used by management.
On Stock Titan, each PLSE filing is supplemented with AI-generated explanations that clarify technical language, summarize key sections and point out items such as clinical trial descriptions, regulatory designations and capital structure changes. Users can also monitor Form 4 insider transaction filings when available to see how officers and directors transact in company stock. Together, these tools allow investors, analysts and clinicians to quickly understand the implications of Pulse Biosciences’ SEC filings without reading every line of each document.
Pulse Biosciences, Inc. furnished an update on its first-in-human clinical study of the nPulse Cardiac Catheter System for atrial fibrillation, highlighting sustained procedure success and efficiency metrics from a multicenter feasibility study in Europe.
At Heart Rhythm 2026, investigators reported 100% procedural success at 6 months in 95 evaluable patients and 96% procedural success at one year in 51 evaluable patients, with a 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year. Among 177 treated patients, serious adverse events related to the primary safety endpoint occurred in 1.7% of subjects. The company also posted an updated investor presentation and a detailed press release with these results.
Pulse Biosciences, Inc. furnished an updated investor presentation on its website, highlighting progress and plans across its cardiac and soft tissue programs. The deck adds new details on the pivotal clinical study of its nsPFA Cardiac Catheter for treating atrial fibrillation, describes the next-generation nPulse cardiac catheter under development, and outlines 2026 corporate goals in electrophysiology, cardiac surgery and soft tissue ablation. The company may use this presentation in meetings with investors and analysts. The investor deck is provided as an exhibit and is treated as furnished, not filed, under securities laws, and includes forward-looking statements subject to risks and uncertainties.
Pulse Biosciences, Inc. appointed Liane R. Teplitsky as Chief Operating Officer effective April 8, 2026, and expanded Dr. David Kenigsberg’s role as full-time Chief Medical Officer to support development of its nPulse cardiac catheter ablation system.
Ms. Teplitsky’s at-will Employment Agreement provides a $525,000 annual base salary and a target bonus equal to 70% of base salary, plus eligibility for standard executive benefits. She received a nonstatutory stock option to purchase 700,000 shares at $19.06 per share and 200,000 performance-based restricted stock units under the 2017 Inducement Equity Incentive Plan, with time-based and performance-based vesting tied to market capitalization and revenue milestones.
Pulse also granted inducement options covering 7,700 shares to two other new employees, each with a $19.06 exercise price and four-year time-based vesting.
Pulse Biosciences reported that it has enrolled and treated the first seven patients in its NANOPULSE-AF IDE pivotal clinical study of the nPulse™ Cardiac Catheter System for recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation. The prospective, multicenter investigation plans to enroll about 215 participants across multiple sites in the United States and Europe.
Primary endpoints will be assessed at 6 and 12 months post-ablation to evaluate procedural success and safety. The study builds on a first-in-human feasibility trial that showed 96% procedural success at 12 months and 100% acute success, in a setting where atrial fibrillation recurrence of 20–25% is described as typical. The system uses nanosecond pulsed field ablation energy and is integrated with Abbott’s EnSite X 3D electroanatomical mapping software.
UECKER DARRIN reported acquisition or exercise transactions in this Form 4 filing.
PULSE BIOSCIENCES, INC. reported that Chief Technology Officer Darrin Uecker received a grant of 100,000 Restricted Stock Units. Each RSU represents a contingent right to receive one share of common stock. Following this grant, he holds 100,000 RSUs.
The RSUs are scheduled to fully vest on March 23, 2029, the three-year anniversary of the grant, provided he continues to serve with the company through that date. This is a stock-based compensation award rather than an open-market share purchase or sale.
Pulse Biosciences, Inc. reported that its Compensation Committee granted Chief Technology Officer Darrin R. Uecker a restricted stock unit award covering 100,000 shares of common stock. The award recognizes his continued leadership of the company’s product development efforts for the treatment of atrial fibrillation.
The RSUs vest in full on the third anniversary of the grant date, subject to the terms of the grant agreement and the company’s Amended and Restated 2017 Equity Incentive Plan. This is an equity-based compensation grant designed to align the CTO’s incentives with long-term company performance.
Pulse Biosciences filed an 8-K describing a strategic and organizational realignment to prioritize development and future commercialization of its nPulse Cardiac Catheter Ablation System for treating atrial fibrillation. The company is reallocating capital and resources toward its electrophysiology program after reporting strong feasibility data.
In the near term, the realignment includes reducing headcount in sales and marketing while actively hiring in product development roles. The move follows European feasibility results in over 150 patients that the company describes as demonstrating speed, safety, and durable efficacy, with additional 12‑month follow-up data to be presented at Heart Rhythm 2026.
Pulse Biosciences, Inc. filed an 8-K after announcing first patient enrollments in a multi-center, first-in-human feasibility study of its nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma, a common low-risk thyroid cancer. Initial procedures were successfully completed at Sarasota Memorial Health Care System in Florida and The University of Texas MD Anderson Cancer Center in Texas.
The study plans to enroll 30 patients with tumors under 1.5 cm to evaluate the safety and effectiveness of the Vybrance System, which uses Nanosecond Pulsed Field Ablation (nsPFA) to nonthermally remove cellular tissue while sparing surrounding structures. The system already holds FDA 510(k) clearance for soft tissue ablation and is now being evaluated under an Investigational Device Exemption specifically for thyroid cancer, with the study funded in part by the company.
Pulse Biosciences filed an 8-K to share new long-term clinical data from its nPulse Vybrance Percutaneous Electrode System first-in-human feasibility study for benign thyroid nodules using nsPFA energy. The extension study followed 21 patients for 15–22 months to assess durability of treatment effects.
The company reports an average 74% volume reduction in treated benign thyroid nodules, with no nodule regrowth observed during follow-up and no serious adverse events. Patient-reported outcomes were very strong: 100% of patients were highly satisfied with cosmetic results and 95% were highly satisfied overall at final follow-up, supporting the potential durability and tolerability of this nonthermal ablation approach.
Pulse Biosciences, Inc. furnished an updated investor presentation dated March 2026, which has been posted on its website and attached as Exhibit 99.1. The deck includes summary financial information, details on the next-generation nPulse cardiac catheter under development, and an increased focus on EP cardio ablation products and clinical development following what it describes as unprecedented clinical outcomes data from its EU feasibility study.
The company plans to use this investor presentation, in whole or in part and potentially with modifications, in meetings with investors, analysts, and others. The information is provided under a Reg FD disclosure, is considered "furnished" rather than "filed," and includes forward-looking statements that are subject to risks and uncertainties referenced in the company’s SEC filings.